May 27th, 2020 | 06:00 CEST
New Century Resources, Alcidion Group, Telix Pharmaceutical, Marley Spoon - emerging ASX companies
Table of contents:
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
When Small Cap expert Robert Frost opens the lines again on Friday, the participating investors will have the opportunity to get exciting first-hand information from the presenting company delegates. As Head of Investments at OC Funds Management, Frost knows what is important. Typically, companies have the opportunity to explain their business model and future prospects in 10 to 15 minutes. Participation can also be worthwhile for participants outside of Australia, as many Australian companies are also listed in Europe or North America and shares can be traded during trading hours there.
Registration: Share Cafe Emerging ASX Stocks Webinar
Zinc production in Australia
New Century Resources (ASX: NCZ) is an Australian base metal producer that operates the Century Mine in Queensland and aims to become one of the top 10 zinc producers in the world. The Company acquired the Century Mine in 2016 as a turnaround to benefit from future improvements to the existing mine infrastructure. This work was completed in August 2018 and the mine successfully went into production.
Transformation Partner for Medical Sector
Alcidion Limited (ASX: ALC) has a simple goal: to transform healthcare with intelligent, intuitive technology solutions that meet the needs of hospitals and healthcare facilities worldwide. The company offers a complementary range of software products and services that it claims create a unique offering in the global healthcare market. The solutions include applications that enable communication, task management and clinical decision support at the point of care to improve patient outcomes.
Cancer treatment with individual therapy
Telix Pharmaceutical (ASX: TLX) has a team of drug developers and experts with extensive expertise in radiation biology and oncology. Telix's pipeline currently focuses on cancer treatment. The product development strategy is to closely integrate and add value to the standard treatment, reflecting the modern team-based approach to cancer treatment. Nuclear medicine has always suffered from a lack of commercial critical mass and commitment to late-stage product development. Molecular Targeted Radiation (MTR) offers potentially better informed treatment decisions and truly personalized therapy.
Healthy nutrition for all
The mission of Marley Spoon AG (ASX: MMM) is to bring people back to the delicious, market-fresh and light cuisine. The management has set itself the goal of building large consumer brands that enable families and couples to cook during the week, thus improving the lives of customers and reducing food waste. Marley Spoon believes it will take many years to achieve this goal.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.